Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma

A Phase I/II Study of Lenalidomide Plus Obinutuzumab in Relapsed Indolent Lymphoma

(2020) Nathan H Fowler et al.   BLOOD

Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs

(2019) Matthew J. Matasar et al.   ONCOLOGIST

The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines

(2019) Gro Elise Rødland et al.   Frontiers in Oncology

The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest

(2019) Alexandre Pichard et al.   LEUKEMIA

Combination of 177 Lu-lilotomab with rituximab significantly improves the therapeutic outcome in pre-clinical models of non-Hodgkin's lymphoma

(2018) Ada H. V. Repetto-Llamazares et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients

(2018) Caroline Stokke et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin’s lymphoma

(2018) Thomas D. Rodgers et al.   EXPERT OPINION ON EMERGING DRUGS

Targeting the B cell receptor pathway in non-Hodgkin lymphoma

(2018) Kelly Valla et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study

(2018) Ajay K. Gopal et al.   JOURNAL OF CLINICAL ONCOLOGY

Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib

(2018) Günter Krause et al.   Drug Design Development and Therapy

Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody–Radionuclide Conjugate177Lu-Lilotomab Satetraxetan

(2017) Johan Blakkisrud et al.   JOURNAL OF NUCLEAR MEDICINE

Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177 Lu-Lilotomab Satetraxetan

(2016) Johan Blakkisrud et al.   JOURNAL OF NUCLEAR MEDICINE

Red Marrow–Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177 Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody–Radionuclide Conjugate

(2016) Johan Blakkisrud et al.   JOURNAL OF NUCLEAR MEDICINE

Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial

(2016) Laurie H Sehn et al.   LANCET ONCOLOGY

Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

(2015) Carla Casulo et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma

(2015) Ada H. V. Repetto-Llamazares et al.   PLoS One

Radioimmunotherapy with 177Lu-DOTA-Rituximab: Final Results of a Phase I/II Study in 31 Patients with Relapsing Follicular, Mantle Cell, and Other Indolent B-Cell Lymphomas

(2013) F. Forrer et al.   JOURNAL OF NUCLEAR MEDICINE

Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?

(2011) Jolanta Kunikowska et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours

(2010) Phillip G. Claringbold et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Lymphocytic Toxicity in Patients After Peptide-Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC

(2009) Maribel L. Sierra et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

In vitro characterization of 177Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study

(2009) Flavio Forrer et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING